Fracture risk following intermission of osteoporosis therapy

被引：0

作者：

E.M. Dennison

C. Cooper

J.A. Kanis

O. Bruyère

S. Silverman

E. McCloskey

B. Abrahamsen

D. Prieto-Alhambra

S. Ferrari

机构：

[1] University of Southampton,MRC Lifecourse Epidemiology Unit

[2] University of Oxford,Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences

[3] University of Sheffield,Centre for Metabolic Bone Diseases, University of Sheffield Medical School

[4] Australian Catholic University,Mary McKillop Health Institute

[5] University of Liège,World Health Organization Collaborating Center for Public Health Aspects of Musculoskeletal Health and Ageing, Department of Public Health, Epidemiology and Health Economics

[6] Cedars-Sinai/UCLA Medical Center and OMC Clinical Research Center,Academic Unit of Bone Metabolism, Department of Oncology and Metabolism, The Mellanby Centre For Bone Research

[7] University of Sheffield,Department of Medicine

[8] Holbaek Hospital,OPEN, Institute of Clinical Research

[9] University of Southern Denmark,Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences

[10] University of Oxford,GREMPAL Research Group, Idiap Jordi Gol and CIBERFes

[11] Universitat Autonoma de Barcelona and Instituto de Salud Carlos III,Division of Bone Disease, Faculty of Medicine

[12] Geneva University Hospital,undefined

来源：

Osteoporosis International | 2019年 / 30卷

关键词：

Atypical fracture; Bisphosphonates; Denosumab; Drug holiday;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：1733 / 1743

页数：10

共 50 条

[1] Fracture risk following intermission of osteoporosis therapy
Dennison, E. M.
Cooper, C.
Kanis, J. A.
Bruyere, O.
Silverman, S.
McCloskey, E.
Abrahamsen, B.
Prieto-Alhambra, D.
Ferrari, S.
OSTEOPOROSIS INTERNATIONAL, 2019, 30 (09) : 1733 - 1743
[2] Fracture Risk and Zoledronic Acid Therapy in Men with Osteoporosis
Boonen, Steven
Reginster, Jean-Yves
Kaufman, Jean-Marc
Lippuner, Kurt
Zanchetta, Jose
Langdahl, Bente
Rizzoli, Rene
Lipschitz, Stanley
Dimai, Hans Peter
Witvrouw, Richard
Eriksen, Erik
Brixen, Kim
Russo, Luis
Claessens, Frank
Papanastasiou, Philemon
Antunez, Oscar
Su, Guoqin
Bucci-Rechtweg, Christina
Hruska, Josef
Incera, Elodie
Vanderschueren, Dirk
Orwoll, Eric
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (18) : 1714 - 1723
[3] Bisphosphonate therapy for osteoporosis: combining optimal fracture risk reduction with patient preference
Beard, Mary K.
CURRENT MEDICAL RESEARCH AND OPINION, 2012, 28 (01) : 141 - 147
[4] Osteoporosis in postmenopausal women - Therapy options across a wide range of risk for fracture
Miller, RG
GERIATRICS, 2006, 61 (01) : 24 - 30
[5] Anti-osteoporosis therapy and fracture healing
Sune Larsson
Nicola L. Fazzalari
Archives of Orthopaedic and Trauma Surgery, 2014, 134 : 291 - 297
[6] Anti-osteoporosis therapy and fracture healing
Larsson, Sune
Fazzalari, Nicola L.
ARCHIVES OF ORTHOPAEDIC AND TRAUMA SURGERY, 2014, 134 (02) : 291 - 297
[7] 2020 recommendations for osteoporosis treatment according to fracture risk from the Swiss Association against Osteoporosis (SVGO)
Serge, Ferrari
Kurt, Lippuner
Olivier, Lamy
Christian, Meier
SWISS MEDICAL WEEKLY, 2020, 150 : w20352
[8] Bisphosphonate drug holidays in postmenopausal osteoporosis: effect on clinical fracture risk
Mignot, M. A.
Taisne, N.
Legroux, I.
Cortet, B.
Paccou, J.
OSTEOPOROSIS INTERNATIONAL, 2017, 28 (12) : 3431 - 3438
[9] Timing of osteoporosis therapies following fracture: the current status
Palui, Rajan
Durgia, Harsh
Sahoo, Jayaprakash
Naik, Dukhabandhu
Kamalanathan, Sadishkumar
THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, 2022, 13
[10] Bisphosphonate drug holidays in postmenopausal osteoporosis: effect on clinical fracture risk
M. A. Mignot
N. Taisne
I. Legroux
B. Cortet
J. Paccou
Osteoporosis International, 2017, 28 : 3431 - 3438

← 1 2 3 4 5 →